Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Avandia; BRL 49653; BRL 49653C; Rosiglitazone extended-release; Rosiglitazone maleate; Rosiglitazone XR; RSG XR

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer Bristol-Myers Squibb; GlaxoSmithKline
  • Class Antidementias; Antihyperglycaemics; Antipsoriatics; Small molecules; Thiazolidinediones
  • Mechanism of Action Antioxidants; Peroxisome proliferator-activated receptor agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • No development reported Asthma
  • Discontinued Alzheimer's disease; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 25 Nov 2013 US FDA removes restrictions for use of rosiglitazone-containing drugs in Type 2 diabetes mellitus in the USA
  • 06 Jun 2013 Joint advisory committee to the FDA recommends that rosiglitazone remain available to appropriate patients in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top